Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) which is being evaluated in the US to treat type 2 diabetes as an adjunct to diet and exercise.
Metformin is diabetes medication that acts by reducing the amount of glucose produced by the liver.
Takeda Global Research & Development Center vice president Thomas Strack said the submission reflects the company’s commitment to offer patients with type 2 diabetes a range of therapeutic options.
"The worldwide incidence of type 2 diabetes continues to expand at an alarming rate and we continue our research into additional medications to treat these patients," Strack added.
The FDA’s standard review period for a new application is ten months.